Grifols | GRFS - Loan Capital


Grifols reported EUR10.67B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Arca Biopharma USD 1.49M 1.37M Mar/2009
aTyr Pharma USD 12.51M 12.11M Dec/2025
Bio Path USD 0 0 Mar/2025
Brainstorm Cell Therapeutics USD 0 0 Mar/2025
Capricor Therapeutics USD 3.38M 0 Mar/2025
Cara Therapeutics USD 0 0 Mar/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Grifols EUR 10.67B 564.4M Sep/2025
Immunic USD 0 0 Jun/2024
Infinity Pharmaceuticals USD 0 0 Jun/2022
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 107.51M 10.35M Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
TherapeuticsMD USD 0 0 Mar/2022